Literature DB >> 19384601

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis.

Shawna Tazik1, Shakevia Johnson, Deyin Lu, Chandra Johnson, Moussa B H Youdim, Craig A Stockmeier, Xiao-Ming Ou.   

Abstract

Stress can affect the brain and lead to depression; however, the molecular pathogenesis is unclear. An association between stress and stress-induced hypersecretion of glucocorticoids occurs during stress. Dexamethasone (a synthetic glucocorticoid steroid) has been reported to induce apoptosis and increase the activity of monoamine oxidase (MAO) (Youdim et al. 1989). MAO is an enzyme for the degradation of aminergic neurotransmitters; dopamine, noradrenaline and serotonin and dietary amines and MAO inhibitors are classical antidepressant drugs. In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells and glioblastoma 1242-MG cells. Dexamethasone reduced cell viability as measured by MTT test, but rasagiline, selegiline, and 1-R-aminoindan could significantly prevent dexamethasone-induced brain cell death. Among three drugs, rasagiline had the highest neuroprotective effect. Furthermore, the inhibitory effects of these drugs on MAO B catalytic activity and on apoptotic DNA damage (TUNEL staining) were examined. Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan. In summary, the greater neuroprotective effect of rasagiline may be associated with the combination of the parent drug and its metabolite 1-R-aminoindan.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384601      PMCID: PMC2754804          DOI: 10.1007/s12640-009-9030-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  42 in total

1.  Treatment of depression with antiglucocorticoid drugs.

Authors:  O M Wolkowitz; V I Reus
Journal:  Psychosom Med       Date:  1999 Sep-Oct       Impact factor: 4.312

Review 2.  The therapeutic potential of monoamine oxidase inhibitors.

Authors:  Moussa B H Youdim; Dale Edmondson; Keith F Tipton
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

3.  The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.

Authors:  M B Youdim; A Wadia; W Tatton; M Weinstock
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

4.  Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid.

Authors:  R M Geha; I Rebrin; K Chen; J C Shih
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

Review 5.  Corticosteroids and the brain.

Authors:  E R de Kloet; J M Reul; W Sutanto
Journal:  J Steroid Biochem Mol Biol       Date:  1990-11-20       Impact factor: 4.292

Review 6.  The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

Authors:  Moussa B H Youdim
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

Review 7.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

8.  Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes.

Authors:  P Carlo; E Violani; M Del Rio; M Olasmaa; S Santagati; A Maggi; G B Picotti
Journal:  Brain Res       Date:  1996-03-04       Impact factor: 3.252

9.  Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls.

Authors:  J J Mann; R D Kaplan; E D Bird
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 10.  Monoamine oxidase inhibitors. A perspective on their use in the elderly.

Authors:  H P Volz; C H Gleiter
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

View more
  12 in total

1.  Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B.

Authors:  Kevin Chen; Xiao-Ming Ou; Jason Boyang Wu; Jean C Shih
Journal:  Mol Pharmacol       Date:  2010-10-27       Impact factor: 4.436

2.  Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

3.  A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage.

Authors:  Xiao-Ming Ou; Craig A Stockmeier; Herbert Y Meltzer; James C Overholser; George J Jurjus; Lesa Dieter; Kevin Chen; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Mark C Austin; Jia Luo; Akira Sawa; Warren May; Jean C Shih
Journal:  Biol Psychiatry       Date:  2009-12-22       Impact factor: 13.382

4.  Biochemical and genetic alterations of oxidant/antioxidant status of the brain in rats treated with dexamethasone: protective roles of melatonin and acetyl-L-carnitine.

Authors:  Naglaa Assaf; Aziza B Shalby; Wagdy K B Khalil; Hanaa H Ahmed
Journal:  J Physiol Biochem       Date:  2011-10-11       Impact factor: 4.158

Review 5.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

6.  Chronic Social Stress and Ethanol Increase Expression of KLF11, a Cell Death Mediator, in Rat Brain.

Authors:  Jeremy Duncan; Niping Wang; Xiao Zhang; Shakevia Johnson; Sharonda Harris; Baoying Zheng; Qinli Zhang; Grazyna Rajkowska; Jose Javier Miguel-Hidalgo; Donald Sittman; Xiao-Ming Ou; Craig A Stockmeier; Jun Ming Wang
Journal:  Neurotox Res       Date:  2015-03-05       Impact factor: 3.911

7.  Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats.

Authors:  Manju V Subramanian; T J James
Journal:  Cell Stress Chaperones       Date:  2010-03-13       Impact factor: 3.667

8.  The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

Authors:  Shakevia Johnson; Shawna Tazik; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Junming Wang; Grazyna Rajkowska; Xiao-Ming Ou
Journal:  Front Neurosci       Date:  2010-11-02       Impact factor: 4.677

9.  Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.

Authors:  Keiko Inaba-Hasegawa; Yukihiro Akao; Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2012-09-12       Impact factor: 3.575

10.  Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

Authors:  A Machado; A J Herrera; J L Venero; M Santiago; R M de Pablos; R F Villarán; A M Espinosa-Oliva; S Argüelles; M Sarmiento; M J Delgado-Cortés; R Mauriño; J Cano
Journal:  ISRN Neurol       Date:  2011-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.